Physician
Andrew Fond, M.D.
According to 2025 Medicare claims, Andrew Fond, M.D. (NPI: 1588859235) practices pain management in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is SOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP (NPI: 1952333478) and primary practice location at 91367-6701.
Fond's data goes back to 2015 and runs through 2024. Part D data shows 417 prescription claims across 150 beneficiaries totaling $16,863 in drug costs, led by Tizanidine Hcl (Tizanidine Hcl). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.
Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $49,046 to $16,863. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.